Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.
Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang MR, Kurosawa G, Sugyo A, Tsuji AB, Higashi T, Kurihara H, Ueno M, Yoshii Y. Hihara F, et al. Among authors: yoshii y. Int J Mol Sci. 2022 May 22;23(10):5807. doi: 10.3390/ijms23105807. Int J Mol Sci. 2022. PMID: 35628616 Free PMC article.
Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts.
Yoshii Y, Yoshimoto M, Matsumoto H, Tashima H, Iwao Y, Takuwa H, Yoshida E, Wakizaka H, Yamaya T, Zhang MR, Sugyo A, Hanadate S, Tsuji AB, Higashi T. Yoshii Y, et al. Oncotarget. 2018 Jun 22;9(48):28935-28950. doi: 10.18632/oncotarget.25649. eCollection 2018 Jun 22. Oncotarget. 2018. PMID: 29989003 Free PMC article.
Usefulness of PET-guided surgery with 64Cu-labeled cetuximab for resection of intrapancreatic residual tumors in a xenograft mouse model of resectable pancreatic cancer.
Igarashi C, Yoshii Y, Tashima H, Iwao Y, Sakurai K, Hihara F, Tachibana T, Yoshida E, Wakizaka H, Akamatsu G, Yamaya T, Yoshimoto M, Matsumoto H, Zhang MR, Nagatsu K, Sugyo A, Tsuji AB, Higashi T. Igarashi C, et al. Among authors: yoshii y. Nucl Med Commun. 2021 Oct 1;42(10):1112-1121. doi: 10.1097/MNM.0000000000001442. Nucl Med Commun. 2021. PMID: 34100794
Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates.
Matsumoto H, Watabe T, Igarashi C, Tachibana T, Hihara F, Waki A, Zhang MR, Tashima H, Yamaya T, Ooe K, Shimosegawa E, Hatazawa J, Yoshida S, Naito K, Kurihara H, Ueno M, Ito K, Higashi T, Yoshii Y. Matsumoto H, et al. Among authors: yoshii y. Pharmaceuticals (Basel). 2021 Sep 23;14(10):950. doi: 10.3390/ph14100950. Pharmaceuticals (Basel). 2021. PMID: 34681174 Free PMC article.
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy.
Yoshimoto M, Yoshii Y, Matsumoto H, Shinada M, Takahashi M, Igarashi C, Hihara F, Tachibana T, Doi A, Higashi T, Fujii H, Washiyama K. Yoshimoto M, et al. Among authors: yoshii y. Pharmaceutics. 2021 Oct 16;13(10):1706. doi: 10.3390/pharmaceutics13101706. Pharmaceutics. 2021. PMID: 34683999 Free PMC article.
474 results